Androgen deprivation therapy
PROSPER trial: Enzalutamide reduces the risk of metastasis or death by 71% in men with non-metastatic castration-resistant prostate cancer
The results from the phase 3 PROSPER trial in patients with non-metastatic ( M0 ) castration-resistant prostate cancer ( CRPC...
SPARTAN trial, Apalutamide, an androgen receptor inhibitor, improves median metastasis-free survival by more than two years in patients with non-metastatic castration-resistant prostate cancer
New findings were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium ( ASCO GU ) in San...
Prostate cancer: link between androgen deprivation therapy and dementia
A new analysis of patients who have undergone treatment for prostate cancer shows a connection between androgen deprivation therapy (...
Abiraterone acetate provides significant clinical benefit in patients with high-risk metastatic hormone-naïve prostate cancer, improving overall survival and radiographic progression-free survival
Data from the pivotal phase 3 LATITUDE clinical trial showed Abiraterone acetate ( Zytiga ) plus Prednisone, in combination with...
Abiraterone for prostate cancer not previously treated with hormone therapy
STAMPEDE is a multigroup, multistage platform trial protocol investigating the efficacy of additional therapy at the time of inception of...
Metastatic prostate carcinoma: Enzalutamide, a hormone therapy, improves survival
In a phase III clinical trial, the hormone therapy Enzalutamide ( Xtandi ) extended survival in men with metastatic prostate...
Early prostate cancer: watchful waiting versus radical prostatectomy
Radical prostatectomy reduces mortality among men with localized prostate cancer; however, important questions regarding long-term benefit remain. Between 1989 and 1999,...
Increased survival in men with metastatic prostate cancer who receive Docetaxel when starting hormone therapy
According to early results from a randomized controlled clinical trial, men with hormone-sensitive metastatic prostate cancer who received the chemotherapy...
Androgen deprivation therapy for treatment of prostate cancer associated with increased risk of kidney injury
In a study that included more than 10,000 men with nonmetastatic prostate cancer, use of androgen deprivation therapy ( ADT...
Androgen deprivation therapy for treatment of advanced or metastatic prostate cancer: antiandrogens associated with hepatotoxicity
Antiandrogens are a class of drugs used in androgen deprivation therapy for the treatment of advanced or metastatic prostate cancer....
Risk of serious infections, dermatologic adverse events and suppression of bone turnover, including osteonecrosis of the jaw, with use of Prolia
Amgen has informed physicians of important safety information for Prolia ( Denosumab ) and updates to the Prescribing Information.Prolia was...
Prolia increases bone density, cuts fracture risk in prostate cancer survivors
Twice-yearly treatment with Denosumab ( Prolia ) has increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy...
Determinants of androgen deprivation therapy use for prostate cancer: role of urologist
Androgen deprivation therapy, which blocks steroid hormones called androgens, is used in around 50% of prostate cancer patients. It is...
Androgen deprivation therapy does not keep localized prostate cancer from spreading
Researchers, at Oregon Health & Science University, wanted to know if depriving men of testosterone actually keeps cancer from spreading...
Prostate cancer: TURP patients with intermediate PSA should be considered high-risk
Researchers at Fox Chase Cancer Center recommend more aggressive treatment for men whose prostate cancers occurred after transurethral resection of...